Regional Anticoagulation with Citrate is Superior to Systemic Anticoagulation with Heparin in Critically Ιll Patients Undergoing Continuous Venovenous Hemodiafiltration
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Short hemofilter survival and anticoagulation-related life-threatening complications are major problems in systemic anticoagulation with heparin (SAH) for continuous renal replacement therapy (CRRT). The present study examined if regional anticoagulation with citrate (RAC) using commercially available solutions can overcome the associated problems of SAH to produce economical benefits. Methods: Forty-six patients were assigned to receive SAH or RAC. We assessed the coagulation state, clinical outcomes, and adverse events. A Kaplan-Meier analysis was used to estimate hemofilter life span. The economical benefit related to the prolonged hemofilter survival was examined on the basis of the average daily cost. Results: The mean age of patients was 66.5 ± 13.8 years and the majority were male (60.9%). While elective discontinuation was most common cause of early CRRT interruption in the RAC group (34.3%, p < 0.01), hemofilter clotting was most prevalent in the SAH group (82.2%, p < 0.01). The patient metabolic and electrolyte control and survival rate were not different between the two groups. When compared with the RAC group, the anticoagulation-associated bleeding was a major complication in the SAH group (15.0% vs. 61.5%, p < 0.01). Regional anticoagulated hemofilters displayed a significantly longer survival time than systemic anticoagulated hemofilters (59.5 ± 3.8 hr vs. 15.6 ± 1.3 hr, p < 0.01). Accordingly, the mean daily continuous venovenous hemodiafiltration costs in the RAC and SAH groups were $575 ± 268 and $1,209 ± 517, respectively (p < 0.01). Conclusions: RAC prolonged hemofilter survival, displaying an economical benefit without severe adverse effects. The present study therefore demonstrates that RAC, using commercially available solutions, may be advantageous over SAH as a cost-effective treatment in CRRT.
Abstract
Background/Aims: Short hemofilter survival and anticoagulation-related life-threatening complications are major problems in systemic anticoagulation with heparin (SAH) for continuous renal replacement therapy (CRRT). The present study examined if regional anticoagulation with citrate (RAC) using commercially available solutions can overcome the associated problems of SAH to produce economical benefits. Methods: Forty-six patients were assigned to receive SAH or RAC. We assessed the coagulation state, clinical outcomes, and adverse events. A Kaplan-Meier analysis was used to estimate hemofilter life span. The economical benefit related to the prolonged hemofilter survival was examined on the basis of the average daily cost. Results: The mean age of patients was 66.5 ± 13.8 years and the majority were male (60.9%). While elective discontinuation was most common cause of early CRRT interruption in the RAC group (34.3%, p < 0.01), hemofilter clotting was most prevalent in the SAH group (82.2%, p < 0.01). The patient metabolic and electrolyte control and survival rate were not different between the two groups. When compared with the RAC group, the anticoagulation-associated bleeding was a major complication in the SAH group (15.0% vs. 61.5%, p < 0.01). Regional anticoagulated hemofilters displayed a significantly longer survival time than systemic anticoagulated hemofilters (59.5 ± 3.8 hr vs. 15.6 ± 1.3 hr, p < 0.01). Accordingly, the mean daily continuous venovenous hemodiafiltration costs in the RAC and SAH groups were $575 ± 268 and $1,209 ± 517, respectively (p < 0.01). Conclusions: RAC prolonged hemofilter survival, displaying an economical benefit without severe adverse effects. The present study therefore demonstrates that RAC, using commercially available solutions, may be advantageous over SAH as a cost-effective treatment in CRRT.
참고문헌 (14)
- Palsson R, "Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding", Kidney Int, 55, pp.1991~1997 (1999)
- Tolwani AJ, "A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance", Clin J Am Soc Nephrol, 1, pp.79~87 (2006)
- Kutsogiannis DJ, "Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients", Kidney Int, 67, pp.2361~2367 (2005)
- Cointault O, "Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions", Nephrol Dial Transplant, 19, pp.171~178 (2004)
- Munjal S, "Regional citrate anticoagulation in continuous venovenous haemofiltration using commercial preparations", Nephrology (Carlton), 11, pp.405~409 (2006)
- Monchi M, "Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study", Intensive Care Med, 30, pp.260~265 (2004)
- Ronco C, "Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial", Lancet, 356, pp.26~30 (2000)
- Tan HK, "Continuous veno-venous hemofiltration without anticoagulation in high-risk patients", Intensive Care Med, 26, pp.1652~1657 (2000)
- Uchino S, "Continuous is not continuous: the incidence and impact of circuit “down-time” on uraemic control during continuous veno-venous haemofiltration", Intensive Care Med, 29, pp.575~578 (2003)
- Bagshaw SM, "Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system", J Crit Care, 20, pp.155~161 (2005)
- Uchino S, "Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators", Intensive Care Med, 33, pp.1563~1570 (2007)
- Tolwani AJ, "Simplified citrate anticoagulation for continuous renal replacement therapy", Kidney Int, 60, pp.370~374 (2001)
- Mehta RL, "Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients", Kidney Int, 38, pp.976~981 (1990)
- Brophy PD, "Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT)", Nephrol Dial Transplant, 20, pp.1416~1421 (2005)